Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    seascape
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer
Conditions: Platinum-resistant Ovarian Cancer;   Platinum-resistant Fallopian Cancer;   Platinum-resistant Peritoneal Cancer
Interventions: Biological: CRS-207;   Drug: epacadostat (INCB024360)
2 Active, not recruiting An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation

Study has passed its completion date and status has not been verified in more than two years.